Taking the measure of glycans
When Lorna De Leoz invited labs to participate in her glycomics study, she hoped for 20 responses. Instead, she was deluged by emails from around the world.
De Leoz, then a research chemist at the National Institute for Standards and Technology was planning a study on how pharmaceutical and academic laboratories measure glycans, complex carbohydrate molecules that cells use to posttranslationally modify various proteins. The project, the subject of a recent paper in the journal Molecular & Cellular Proteomics, grew to include 76 participating labs.The flood of responses, including from many well-known pharmaceutical companies, illustrates the industry’s appetite for a better understanding of protein glycosylation. A growing number of drugs are made from proteins — most often antibodies — and this is a big variable in manufacturing them.
Glycans make up just 3% of the weight of an antibody-based drug, but they have an outsized impact. A change in glycosylation from one batch to the next can alter a drug’s binding to its target or the likelihood that it will be attacked by the patient’s immune system. To make sure patients receive the safest and most effective medicine, researchers must be able to keep track of the glycosylation status of antibody drugs.
Stephen Stein, a fellow at NIST’s mass spectrometry data center, was the senior author of the study. “Glycosylation is one of the most important physical-chemical aspects of biology,” he said, “but one of the most difficult to analyze.”
Glycans’ complex and heterogeneous structures make analysis difficult. Unlike macromolecules such as DNA and proteins, which are made of a linear chain of subunits, sugars can link in several places, building branched chains. Complicating matters, while those single-chain macromolecules are usually made by referring to a template, glycans are more free-form. A scrum of enzymes, each making its signature modification, determines their final structure.
Researchers have developed many methods to measure glycosylation, and their results can vary. That’s where the NIST comes in: The institute is dedicated to establishing shared measurements. To help glycomics scientists get clear about what they’re measuring, De Leoz sent each participating lab a sample of the same antibody, a failed drug candidate. It took almost a month to pack up samples and fill out dozens of customs forms.
The glycomics techniques among the participating labs were diverse. Some measurements, often used in manufacturing, are optimized to find the exact quantity of one or two glycan structures; others, more often used in academia, are better suited to showing the broad scope of glycan types that are present. “There was no one method that was clearly better than all the others,” Stein said. “They all have different advantages and disadvantages.”
The NIST researchers used a statistical approach to combine measurements from disparate labs into a list of consensus estimates of the concentration of certain glycan compositions. The NIST will leave it up to the research community to figure out which measurement approach to use. MCP Editor-in-Chief Alma Burlingame said he hopes the paper will “point out to the biopharma industry and glycoanalytical community the urgent need to bring some methodological rigor to bear in the popular and important field of FDA-regulated antibodies.”
Enjoy reading 91影库Today?
Become a member to receive the print edition four times a year and the digital edition monthly.
Learn moreGet the latest from 91影库Today
Enter your email address, and we鈥檒l send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles

Hope for a cure hangs on research
Amid drastic proposed cuts to biomedical research, rare disease families like Hailey Adkisson鈥檚 fight for survival and hope. Without funding, science can鈥檛 鈥渃atch up鈥 to help the patients who need it most.

Before we鈥檝e lost what we can鈥檛 rebuild: Hope for prion disease
Sonia Vallabh and Eric Minikel, a husband-and-wife team racing to cure prion disease, helped develop ION717, an antisense oligonucleotide treatment now in clinical trials. Their mission is personal 鈥 and just getting started.

Defeating deletions and duplications
Promising therapeutics for chromosome 15 rare neurodevelopmental disorders, including Angelman syndrome, Dup15q syndrome and Prader鈥揥illi syndrome.

Using 'nature鈥檚 mistakes' as a window into Lafora disease
After years of heartbreak, Lafora disease families are fueling glycogen storage research breakthroughs, helping develop therapies that may treat not only Lafora but other related neurological disorders.

Cracking cancer鈥檚 code through functional connections
A machine learning鈥揹erived protein cofunction network is transforming how scientists understand and uncover relationships between proteins in cancer.

Gaze into the proteomics crystal ball
The 15th International Symposium on Proteomics in the Life Sciences symposium will be held August 17鈥21 in Cambridge, Massachusetts.